Pfizer ( PFE) reported a beat in second quarter earnings Tuesday, and reaffirmed its 2025 guidance of between $61 to $64 ...

Second-quarter adjusted earnings came in at 78 cents a share on revenue of $14.7 billion, beating expectations.

Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...

Pfizer raised its full-year profit forecast on Tuesday while reporting second-quarter results that topped Wall Street estimates, and said it expects to benefit from cost-cutting and a weaker dollar.

Pfizer Inc. raised its profit forecast for the year, with the drugmaker’s ongoing cost cuts helping to make up for a lack of ...

Pfizer stock rises after a strong Q2, boosted by cost savings, pipeline progress, and an upgraded 2025 profit outlook.

Aug 5 - Pfizer (NYSE:PFE) heads into its Q2 earnings release amid growing investor caution. Analysts expect revenue around ...

Pharmaceutical major recorded a revenue jump to $14.65 billion, exceeding the market expectations. The company also raised ...

Pharmaceutical giant Pfizer (PFE) has reported financial results for this year’s second quarter that topped Wall Street forecasts. The New York City-based company announced earnings per share (EPS) of ...

The Health and Human Services secretary said he is reviewing whether to remove the medical experts on the U.S. Preventive Services Task Force who advise on cancer screenings, HIV prevention drugs, and ...

Pfizer's stock soared following robust sales of COVID-19 products and key drugs, leading to stronger-than-expected earnings and an increased profit forecast for 2025.

Many viruses circulate seasonally, picking up as the weather cools in the fall and winter. So it’s true that fewer people get ...